Human Primary Cancer Cells

A more physiologically relevant cancer model

AMSBIO offers primary human cancer cells sourced from a variety of tissue types that allow the study of cancer to be more physiologically relevant. Provided with the original pathological diagnoses and analyzed for key mutations, these primary human cancer cells present the real characteristics of their in vivo state, remain heterogeneous for several passages and thus enhance pharmacogenetic and molecular diagnostic testing abilities. These patient specific cells add to a range of products to help researchers develop more physiologically relevant models to study cell behavior.

Primary Cancer Cells

Here we provide both human primary breast cancer and prostate cancer cells for physiologically relevant cancer studies. For further in vitro patient-derived cancer models, see our Cellaria Cancer Cell Models & Media.

NameDatasheetPacksize Order
Breast tumor primary cancer cells1 x 10^6 cells View
Prostate tumor primary cancer cells1 x 10^6 cells View

Cell Media Kits

These primary cancer cell media kits contain the optimum cell medium to support the primary cell culture of our human breast cancer and prostate cancer cells.

NameDatasheetPacksize Order
Breast Cancer Primary Tumour medium Kit500 ml View
Prosate Cancer Primary Tumour medium Kit500 ml View

The Importance of Patient-Derived Cancer Primary Cells

Despite significant advances in cancer research and treatments, the eradication of the disease remains elusive. This has led to a more urgent focus on precision medicine and advanced treatments like immunotherapy and the use of oncolytic viruses. Patient-derived primary tumor cells offer a more in vivo-like model potentially enhancing the development of targeted personalized therapeutics.

It is known that using immortalized cell lines as surrogates poorly reflects the diverse profiles that tumors have. During long-term culture, immortalized cells adapt to their in vitro environment, and often mask or lose the in vivo phenotypic events being studied, in addition to hiding key epigenetic or immunotherapy markers. These shortfalls highlight a need for new in vitro cancer models that utilize primary tumor cells that more closely reproduce the in vivo cancer microenvironment.